Brief: Wave Life Sciences Announces Positive Interim Data From Phase 1 Inlight Trial Of WVE-007 For Obesity

Wave Life Sciences

08/12/2025 12:31

Dec 8 (Reuters) - WAVE Life Sciences Ltd WVE.O:

WAVE LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 1 INLIGHT TRIAL OF WVE-007 (INHBE) FOR OBESITY; SINGLE DOSE RESULTED IN IMPROVEMENT IN BODY COMPOSITION WITH FAT LOSS SIMILAR TO GLP-1 AT THREE MONTHS WITHOUT MUSCLE LOSS

WAVE LIFE SCIENCES LTD - SINGLE 240 MG DOSE OF WVE-007 REDUCES VISCERAL FAT BY 9.4%

WAVE LIFE SCIENCES LTD - WVE-007 GENERALLY SAFE AND WELL TOLERATED WITH MILD ADVERSE EVENTS

WAVE LIFE SCIENCES LTD - PHASE 2 TRIALS PLANNED FOR WVE-007 AS MONOTHERAPY AND ADD-ON

WAVE LIFE SCIENCES LTD - FURTHER CLINICAL DATA UPDATES EXPECTED IN 1Q 2026 FOR WVE-007

Source text: ID:nGNXbrNhZp

Further company coverage: WVE.O

 ((Reuters.Briefs@thomsonreuters.com;))